A whole-animal platform to advance a clinical kinase inhibitor into new disease space
出版年份 2018 全文链接
标题
A whole-animal platform to advance a clinical kinase inhibitor into new disease space
作者
关键词
-
出版物
Nature Chemical Biology
Volume 14, Issue 3, Pages 291-298
出版商
Springer Nature
发表日期
2018-01-23
DOI
10.1038/nchembio.2556
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- MNK Controls mTORC1:Substrate Association through Regulation of TELO2 Binding with mTORC1
- (2017) Michael C. Brown et al. Cell Reports
- Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
- (2016) Steven A. Lacy et al. CLINICAL PHARMACOKINETICS
- Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia
- (2016) Amir T. Fathi et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis
- (2016) Luciana Audi de Castroneves et al. THYROID
- The Ras-Erk-ETS-Signaling Pathway Is a Drug Target for Longevity
- (2015) Cathy Slack et al. CELL
- Precision medicine in oncology drug development: a pharma perspective
- (2015) Simon J. Hollingsworth DRUG DISCOVERY TODAY
- An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis
- (2015) Theodosia Teo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins
- (2015) Edward Harder et al. Journal of Chemical Theory and Computation
- Applications of Fluorine in Medicinal Chemistry
- (2015) Eric P. Gillis et al. JOURNAL OF MEDICINAL CHEMISTRY
- DFGmodel: Predicting Protein Kinase Structures in Inactive States for Structure-Based Discovery of Type-II Inhibitors
- (2014) Peter Man-Un Ung et al. ACS Chemical Biology
- POVME 2.0: An Enhanced Tool for Determining Pocket Shape and Volume Characteristics
- (2014) Jacob D. Durrant et al. Journal of Chemical Theory and Computation
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- On the Dielectric “Constant” of Proteins: Smooth Dielectric Function for Macromolecular Modeling and Its Implementation in DelPhi
- (2013) Lin Li et al. Journal of Chemical Theory and Computation
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Pancreatic Atrophy — A New Late Toxic Effect of Sorafenib
- (2013) Ségolène Hescot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib in metastatic thyroid cancer
- (2012) Jaume Capdevila et al. ENDOCRINE-RELATED CANCER
- Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
- (2012) Arvin C. Dar et al. NATURE
- Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety
- (2011) Nicholas A. Meanwell CHEMICAL RESEARCH IN TOXICOLOGY
- Meta-analysis of dermatological toxicities associated with sorafenib
- (2011) L. Zhang et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro
- (2011) Yoon Woo Koh et al. ENDOCRINE-RELATED CANCER
- Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
- (2011) Merina Ahmed et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Tubby-RFP balancers for developmental analysis: FM7c 2xTb-RFP, CyO 2xTb-RFP, and TM3 2xTb-RFP
- (2011) Cara Pina et al. GENESIS
- FRED Pose Prediction and Virtual Screening Accuracy
- (2011) Mark McGann Journal of Chemical Information and Modeling
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
- (2011) Theonie Anastassiadis et al. NATURE BIOTECHNOLOGY
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- CHEMISTRY: Fluorous Tags Unstick Messy Chemical Biology Problems
- (2008) D. P. Curran SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started